Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7815009 | 0.83 | SLC6A2 (0.41) | MEN1KMT2ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10017610 | 0.81 | CTRC (0.47) | THRBMEN1KMT2ASIRT2MAPT | |
| SCHEMBL10690598 | 0.80 | MEN1 (0.55) | THRBMEN1KMT2AMAPT | |
| SCHEMBL11673870 | 0.79 | CEL (0.42) | THRBMEN1KMT2ASIRT2SLC6A2 | |
| SCHEMBL657183 | 0.79 | SLC6A2 (0.44) | THRBBACE1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL11317303 | 0.78 | ALDH1A1 (0.47) | THRBMEN1KMT2ASIRT2MAPT | |
| SCHEMBL30975191 | 0.75 | ALDH1A1 (0.38) | THRBMEN1KMT2ASIRT2MAPT | |
| SCHEMBL8030364 | 0.75 | ALDH1A1 (0.38) | THRBMEN1KMT2ASIRT2MAPT | |
| SCHEMBL28293063 | 0.73 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12172558 | 0.73 | CTRB1 (0.44) | THRBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | THRB 1905/4885MEN1 1425/4885KMT2A 998/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | THRB 1905/4885MEN1 1425/4885KMT2A 998/4885 |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | THRB 2465/4885MEN1 4852/4885KMT2A 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.